Mednet Logo

How do you modify TNBC neoadjuvant chemotherapy in patients with multiple sclerosis?

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Emory University School of Medicine
Answered on

This is a good, but tough question with unfortunately no great data to support the safety of immunotherapy combinations in patients with active autoimmune diseases including multiple sclerosis. While the significant improvement in pathologic complete responses with the addition of pembrolizumab to c...

Join for free or sign in to see the full answer